Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sherene Loi

Showing results (181-190 of 325) with videos related to

Pageof 33
Sort By:
JAMA Oncology|July 13, 2023
Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical TrialElisabetta Munzone, Meredith M Regan, Saverio Cinieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast CancerCharlotte Fribbens, Ben O'Leary, Lucy Kilburn, et al.
Science Translational Medicine|June 9, 2017
Combined immune checkpoint blockade as a therapeutic strategy for <i>BRCA1</i>-mutated breast cancerEmma Nolan, Peter Savas, Antonia N Policheni, et al.
The Lancet. Oncology|March 8, 2016
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialMassimo Cristofanilli, Nicholas C Turner, Igor Bondarenko, et al.
JCO Precision Oncology|January 24, 2025
Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2-Low, Hormone Receptor-Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical TrialsStephen J Luen, Lauren C Brown, Courtney T van Geelen, et al.
NPJ Breast Cancer|August 15, 2023
Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancerZhi Ling Teo, Mark J O'Connor, Stephanie Versaci, et al.
Iscience|August 18, 2025
Role of immunosuppressive JNK pathway in the tumor microenvironment among TNBC subtypes in IBCSG trial 22-00Andrea Joaquin Garcia, Takashi Semba, Mattia Rediti, et al.
NPJ Breast Cancer|August 21, 2024
Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502Daniel G Stover, Roberto Salgado, Oleksander Savenkov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2013
Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trialOtto Metzger-Filho, Marion Procter, Evandro de Azambuja, et al.
NPJ Breast Cancer|December 16, 2025
Author Correction: Advancing equitable access to innovation in breast cancerSeamus O'Reilly, Ines Vaz Luis, Virginie Adam, et al.
Pageof 33

Showing results (181-190 of 325) with videos related to

Sort By:
Pageof 33
JAMA Oncology|July 13, 2023
Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical TrialElisabetta Munzone, Meredith M Regan, Saverio Cinieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast CancerCharlotte Fribbens, Ben O'Leary, Lucy Kilburn, et al.
Science Translational Medicine|June 9, 2017
Combined immune checkpoint blockade as a therapeutic strategy for <i>BRCA1</i>-mutated breast cancerEmma Nolan, Peter Savas, Antonia N Policheni, et al.
The Lancet. Oncology|March 8, 2016
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialMassimo Cristofanilli, Nicholas C Turner, Igor Bondarenko, et al.
JCO Precision Oncology|January 24, 2025
Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2-Low, Hormone Receptor-Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical TrialsStephen J Luen, Lauren C Brown, Courtney T van Geelen, et al.
NPJ Breast Cancer|August 15, 2023
Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancerZhi Ling Teo, Mark J O'Connor, Stephanie Versaci, et al.
Iscience|August 18, 2025
Role of immunosuppressive JNK pathway in the tumor microenvironment among TNBC subtypes in IBCSG trial 22-00Andrea Joaquin Garcia, Takashi Semba, Mattia Rediti, et al.
NPJ Breast Cancer|August 21, 2024
Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502Daniel G Stover, Roberto Salgado, Oleksander Savenkov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2013
Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trialOtto Metzger-Filho, Marion Procter, Evandro de Azambuja, et al.
NPJ Breast Cancer|December 16, 2025
Author Correction: Advancing equitable access to innovation in breast cancerSeamus O'Reilly, Ines Vaz Luis, Virginie Adam, et al.
Pageof 33